We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Class of Antibiotics Fights Resistant Bugs

By HospiMedica staff writers
Posted on 17 Jan 2001
A multi-center study has demonstrated that linezolid, (Zyvox), the first of a new class of antibiotics, is as effective as oxacillin-dicloxacillin in curing skin and soft tissue infections caused by Gram-positive bacteria and holds promise for fighting infections caused by resistant Gram-positive bacteria. More...
The study, conducted by researchers at the U.S. Department of Veterans Affairs (Los Angeles, CA, USA) and colleagues, was reported in the December issue of Antimicrobial Agents and Chemotherapy.

In test tube tests, linezolid proved very active against methicillin-resistant Staphylococcus, penicillin-resistant Streptococcus pneumoniae, and staphylococci and enterococci resistant to vancomycin. The new class of antibiotics is called oxazolidinones, which attack bacteria at a different point than any previously developed antibiotics. Linezolid works by interfering with protein production at an early stage. Moreover, laboratory tests have shown that the antibiotic stalls toxin production in toxin-producing Gram positive bacteria, even at linezolid levels well below those needed to actually kill the microbes.

"We haven't had any totally new antibiotics in a long time,” said Dennis L. Stevens, M.D., one of the study's authors and chief of infectious diseases at the Boise Veterans Affairs Medical Center. "Linezolid has an entirely different mechanism of action and looks like it can get some of the resistant bugs. It's a new cannon in our arsenal.” Stevens emphasized the need for more research and pointed out that linezolid cannot kill nonGram-positive bacteria.



Related Links:
Department of Veterans Affairs

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.